AKBA Q3 2020 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$366M

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$60M-34.8% YoY

Gross Profit

$30M49.4% margin

Operating Income

-$58M-96.8% margin

Net Income

-$60M-100.0% margin

EPS (Diluted)

$-0.42

QoQ Revenue Growth

-33.5%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$27M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$676M

Total Liabilities

$358M

Stockholders' Equity

$318M

Cash & Equivalents

$169M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$60M	$92M	-34.8%
Gross Profit	$30M	$54M	-44.8%
Operating Income	-$58M	-$56M	-3.9%
Net Income	-$60M	-$55M	-9.8%

Revenue Segments

Product

$34M57%

License Collaboration And Other Revenue

$26M43%